实用临床医学
實用臨床醫學
실용림상의학
Practical Clinical Medicine
2014年
12期
10-12
,共3页
IgA肾病%黄葵胶囊%雷公藤多苷片%24 h尿蛋白定量%β2-微球蛋白
IgA腎病%黃葵膠囊%雷公籐多苷片%24 h尿蛋白定量%β2-微毬蛋白
IgA신병%황규효낭%뢰공등다감편%24 h뇨단백정량%β2-미구단백
IgA nephropathy%ambrette capsules%tripterygium wilfordii glycoside tablets%24-hour urinary protein excretion%beta 2-microglobulin
目的:探讨黄葵胶囊联合雷公藤多苷片治疗IgA肾病的临床疗效。方法将84例IgA肾病患者按治疗方法的不同分为2组:试验组和对照组,每组42例。2组均采用常规治疗,包括降尿酸、控制血脂和抗凝治疗及控制饮食、适当的运动锻炼。在此基础上,试验组采用黄葵胶囊联合雷公藤多苷片治疗,对照组采用雷公藤多苷片治疗。观察2组治疗前和治疗12周后总胆固醇(TC)、三酰甘油(TG)、血尿素氮(BUN)、血肌酐和24 h尿蛋白定量、尿视黄醇结合蛋白(RBP)和尿2-微球蛋白(2-MG)的变化及临床疗效、不良反应的情况。结果试验组总有效率明显高于对照组(P<0.05)。2组治疗12周后TC、TG、BUN及24 h尿蛋白定量、RBP和2-MG水平均较治疗前明显下降(P<0.05)。治疗12周后,试验组血肌酐水平较治疗前明显下降,TC、TG、BUN及24 h尿蛋白定量、RBP和2-MG水平均较对照组明显下降(均P<0.05),血肌酐水平较对照组无明显变化(P>0.05)。2组不良反应发生率比较差异有统计学意义(P<0.05)。结论雷公藤多苷片联合黄葵胶囊治疗IgA肾病,能够明显提高临床疗效,降低尿蛋白水平,不良反应少。
目的:探討黃葵膠囊聯閤雷公籐多苷片治療IgA腎病的臨床療效。方法將84例IgA腎病患者按治療方法的不同分為2組:試驗組和對照組,每組42例。2組均採用常規治療,包括降尿痠、控製血脂和抗凝治療及控製飲食、適噹的運動鍛煉。在此基礎上,試驗組採用黃葵膠囊聯閤雷公籐多苷片治療,對照組採用雷公籐多苷片治療。觀察2組治療前和治療12週後總膽固醇(TC)、三酰甘油(TG)、血尿素氮(BUN)、血肌酐和24 h尿蛋白定量、尿視黃醇結閤蛋白(RBP)和尿2-微毬蛋白(2-MG)的變化及臨床療效、不良反應的情況。結果試驗組總有效率明顯高于對照組(P<0.05)。2組治療12週後TC、TG、BUN及24 h尿蛋白定量、RBP和2-MG水平均較治療前明顯下降(P<0.05)。治療12週後,試驗組血肌酐水平較治療前明顯下降,TC、TG、BUN及24 h尿蛋白定量、RBP和2-MG水平均較對照組明顯下降(均P<0.05),血肌酐水平較對照組無明顯變化(P>0.05)。2組不良反應髮生率比較差異有統計學意義(P<0.05)。結論雷公籐多苷片聯閤黃葵膠囊治療IgA腎病,能夠明顯提高臨床療效,降低尿蛋白水平,不良反應少。
목적:탐토황규효낭연합뢰공등다감편치료IgA신병적림상료효。방법장84례IgA신병환자안치료방법적불동분위2조:시험조화대조조,매조42례。2조균채용상규치료,포괄강뇨산、공제혈지화항응치료급공제음식、괄당적운동단련。재차기출상,시험조채용황규효낭연합뢰공등다감편치료,대조조채용뢰공등다감편치료。관찰2조치료전화치료12주후총담고순(TC)、삼선감유(TG)、혈뇨소담(BUN)、혈기항화24 h뇨단백정량、뇨시황순결합단백(RBP)화뇨2-미구단백(2-MG)적변화급림상료효、불량반응적정황。결과시험조총유효솔명현고우대조조(P<0.05)。2조치료12주후TC、TG、BUN급24 h뇨단백정량、RBP화2-MG수평균교치료전명현하강(P<0.05)。치료12주후,시험조혈기항수평교치료전명현하강,TC、TG、BUN급24 h뇨단백정량、RBP화2-MG수평균교대조조명현하강(균P<0.05),혈기항수평교대조조무명현변화(P>0.05)。2조불량반응발생솔비교차이유통계학의의(P<0.05)。결론뢰공등다감편연합황규효낭치료IgA신병,능구명현제고림상료효,강저뇨단백수평,불량반응소。
Objective To explore the curative effect of ambrette capsules combined tripterygium wilfordii glycoside tablets on IgA nephropathy. Methods Eighty-four patients with IgA nephropathy received conventional therapy (lowering uric acid, lipid control, anticoagulation treatment, diet control and proper exercise). In addition, these patients were treated with tripterygium wilfordii glycoside tablets alone (control group, n=42) or in combination with ambrette capsules (experimental group, n=42). The total cholesterol(TC), triacylglycerol (TG), blood urea nitrogen (BUN), serum creatinine, 24-hour urinary protein excretion, urinary retinol binding protein (RBP) and urinary 2-microglobulin (2-MG) were measured before and after treatment for 12 weeks. Furthermore, clinical efficacies and adverse reactions were observed in both groups. Results The total effective rate in experimental group was significantly higher than that in control group (P<0.05). The levels of TC, TG, BUN, 24-hour urinary protein excretion, RBP and 2-MG decreased in both groups and levels of serum creatinine decreased in experimental group after treatment for 12 weeks(P<0.05). Compared with control group, the levels of TC, TG, BUN, 24-hour urinary protein excretion, RBP and 2-MG levels decreased in experimental group after treatment for 12 weeks (P<0.05). No significant difference in levels of serum creatinine was found between the two groups (P>0.05). However, the difference in incidence of adverse reactions was significant between the two groups (P<0.05). Conclusion Ambrette capsules combined tripterygium wilfordii glycoside tablets can improve curative effect, decrease urine protein levels and reduce adverse reactions in patients with IgA nephropathy.